anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cervical spinal cord injury (cSCI) results in physical impairment and limited mobility, with the most severe cSCI necessitating wheelchair use for ambulation and impaired upper extremity function resulting in subsequent chronic comorbidities. These comorbidities may include psychosocial, cardiovascular, metabolic and respiratory consequences, as well as a significant socioeconomic burden. The economic burdens for persons with cSCI, their families, and society are increasing at an alarming rate, especially with decreasing mortality due to advances in medical interventions. Restoring some degree of upper extremity and hand function would improve overall functional ability and quality of life. Through physical rehabilitation, upper extremity function can improve, but gains are limited for people with the most severe, motor-complete cSCI. Attempts have been made to restore and improve upper extremity and hand function using implanted epidural stimulation of the cervical spinal cord, but alternatives to this invasive therapy are warranted to maximize the amount of people who may benefit from enhanced motor activation.

The total study duration is 30 weeks. The first 4 weeks will start and end with baseline assessments (Baseline 1 \&2). The rest of this 4-week period will consist of 2 sessions/week of education and optimization provided to the participant and a caregiver, to instruct them to use the TS device and blood pressure machine and carry out massed practice training for both groups. The first two weeks of this 4-week phase will occur onsite in the laboratory, and the second two weeks of this 4-week phase will occur at home via telehealth to familiarize participants and companions with the telehealth platform - however, if the participant and companion desire more on-site instruction, they may come into the lab to do this during this time as well. Following the first 4-week phase, 16 weeks of 3 sessions/week of BES+TS or BES+sham TS training at home with supervision from the research team via telehealth will occur.

In the week following completion of the intervention, post-intervention outcome measures assessments will take place. There will then be an 8-week washout period where participants will receive no training. Following the 8-week washout, participants will be asked to come back to the lab for one more follow-up assessment of outcome measures to test any long-term effects of the intervention.
BACKGROUND: A technique called in-water resuscitation (IWR) was devised on a surfboard to ventilate persons who seemingly did not breathe upon a water rescue. Despite IWR still raises uncertainties regarding its applicability, this technique is recommended by the International Liaison Committee for Resuscitation (ILCOR). Thus, this study aimed to evaluate the feasibility of IWR with a rescue board before and during towing and, to compare rescue times and rescue-associated fatigue levels between rescues with rescue breath attempts and without (SR).
METHODS: A randomized crossover pilot test was conducted: 1) IWR test with pocket mask and, 2) Conventional SR test. IWR tests were conducted using a Laerdal ResusciAnne manikin (Stavanger, Norway). Three groups of variables were recorded: a) rescue time (in s), b) effective ventilations during rescue, and c) rating of perceived effort (RPE).
RESULTS: Focusing on the rescue time, the performance SR was significantly faster than IWR rescue which took 61 s longer to complete the rescue (Z = -2.805; p = 0.005). No significant differences were found between techniques for the RPE (T = -1.890; p = 0.095). In the IWR analysis, lifeguards performed an average of 27 ± 12 rescue breaths.
CONCLUSION: The application of IWR on a rescue board is feasible both at the time of rescue and during towing. It shortens the reoxygenation time but delays the arrival time to shore. Both IWR and SR result in similar levels of perceived fatigue.
Methods, devices, and systems for determining a presence of appendicitis are provided. In one aspect, a method includes receiving a medical image associated with the patient. Further, the method includes determining, using at least one trained machine learning model, an anatomical position of the appendix in the medical image. Additionally, the method includes determining, using the at least one trained machine learning model, a dimension associated with the appendix in the medical image. The method also includes identifying if the dimension associated with the appendix is above a pre-defined threshold. Furthermore, the method includes generating a notification on an output unit if the dimension associated with the appendix is above the pre-defined threshold, wherein dimension associated with the appendix being above the pre-defined threshold indicates presence of appendicitis in the patient.
Boleda Supramolecular Active Zinc (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
After completion of the 28 day RCT with a control group and an intervention group, we conducted a trial extension for an additional 28 days. During that time, the original control group was trained in the use of the portable stress management device and used it, without support of the research team, for 28 days. Also during that time, the original intervention group were told that they could keep the PSMD and use it as they like. At the end of the 28 day trial extension, stress, and physiological parameters were measured again. For the initial control group, this allowed us to test effectiveness of the PSMD (real life 1 hr training on the device then unsupported use). For the initial intervention group, this allowed us to see if any effects of using the PSMD were maintained for an additional 28 days, without ongoing support from the research team.
Participants with baseline weight \<60 kg received once every 2 weeks (Q2W) subcutaneous (SC) injections of 200 milligrams (mg) dupilumab following a loading dose of 400 mg on day 1. Participants with baseline weight ≥60 kg received Q2W SC injections of 300 mg dupilumab following a loading dose of 600 mg on day 1.
TRULICITY has been studied in adults as monotherapy and in combination with metformin, sulfonylurea, metformin and sulfonylurea, metformin and thiazolidinedione, sodium-glucose co-transporter-2 inhibitors (SGLT2i) with or without metformin, basal insulin with or without metformin, and prandial insulin with or without metformin. TRULICITY has also been studied in patients with type 2 diabetes mellitus and moderate to severe renal impairment.

Dose escalation was performed in one trial in adults with TRULICITY doses up to 4.5 mg added to metformin. All other clinical studies in adults evaluated TRULICITY 0.75 mg and 1.5 mg without dose escalation; patients were initiated and maintained on either 0.75 mg or 1.5 mg for the duration of the trials [see Clinical Studies (14.2, 14.3, 14.4)].

TRULICITY 0.75 mg and 1.5 mg was studied in pediatric patients 10 years of age and older with type 2 diabetes in combination with or without metformin and/or basal insulin treatment [see Clinical Studies (14.6)].

In patients with type 2 diabetes mellitus, TRULICITY produced reductions from baseline in HbA1c compared to placebo. No overall differences in glycemic effectiveness were observed across demographic subgroups (age, gender, race/ethnicity, duration of diabetes).

A cardiovascular outcomes trial was conducted in adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors. Patients were randomized to TRULICITY 1.5 mg or placebo both added to standard of care. TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke [see Clinical Studies (14.5)].
An exemplary medication order processing system ( 10 ) includes a plurality of nursing stations ( 12, 14, 16 ). Physician orders prescribing medications for patients are faxed from the nursing stations to a computer which is included in an interchange fax station ( 28 ) located at the pharmacy. Physician orders for medications are selectively sent to either a priority or normal fax number based on the urgency associated with delivering the medication to the patient. The interchange fax station is operative to prioritize the orders and to present them to pharmacists working at pharmacist work stations ( 40, 42 ). Pharmacist work stations are enabled to review, electronically annotate, and input orders reviewed at the pharmacy work station into a pharmacy order system of the facility. Input to the pharmacy order system results in the medication being administered to the patient. Pharmacists are also enabled to handle discrepancies and to present issues to the originators of the orders so as to resolve questions before the input of the medication order into the pharmacy order system.
Among older persons, age-related impairments cause loss of postural control and balance that result in pain, independency and disability. One of the most common geriatric syndromes and most serious health issue threatening the independency of older persons is fall. The impact of these fall-related injuries on older person, families and societies and its fruitful intervention has made this issue important worldwide. Approximately 28-35% of people aged 65 years and 32-42% of aged 70 years' experience falls annually and 10% suffer serious injury such as, fracture, severe head trauma and joint dislocation. The incidence rate of fall is higher in hospitalized and residents of nursing home. It rises from middle age and peaks in person above 80 years. The risk factors associated with falls are, lower extremity muscle weakness, gait or balance deficits, use of an assistive device, cognitive impairment, visual deficit, arthritis and impaired activities of daily living . Different scales and tests are used for risk factors for falls, balance and mobility such as Berg Balance Scale, Time up and go test and dynamic gait index and Fullerton Advanced Balance Scale. One of these scales Performance-Oriented Mobility Assessment (POMA) scale. POMA scale has acceptable reliability and validity as compared to FRT and TUG in elderly. The advantages of this scale are; applicability, low cost, easy to administer, no equipment is needed other than a standard chair and stopwatch, evaluates functional activities and assesses both balance (POMA-B) and gait components (POMA-G)Originally POMA scale was used to assess risk of fall in institutionalized populations but later on used as an assessment tool for mobility and determine effects of interventions.

The POMA has found to be widely used in patients who have dynamic and reactive balance deficits. It comprises 16 items (9 balance and 7 gait related). Total time taken for administration is approximately 10 minutes and total score is 28; 16 is balance and 12 is gait score. Some Items are scored dichotomously (can/cannot perform) and others are scored 0, 1 or 2 points for quality of performance. The higher scores show low fall risk and better balance while lower score predicts poorer balance and greater risk of fall. The score 19-24/28 indicates moderate risk for falling while score \<19 indicates a "high" risk for falling.
The invention relates to walnut oil intralipid and process for preparation, belonging to the technical field of food and drug. The formulation comprises pure walnut oil, refining lecithin, pure glycerin, caustic soda and pyrogen-free pure water. The basic preparing procedures are as follows: pure walnut oil, refining lecithin, glycerin and water are vigorously stirred into primary milk and the pH value of the primary milk is adjusted to 7.5-8.5 through little caustic soda solution, and then high-pressured and homogenized, filtered by a filter, bottled, sealed and sterilized. The walnut oil intralipid is an artificial chyle product which is prepared by simulating natural chyle granules existing in blood and can be intravenously injected as 'parenteral nutrient solution' to rescue lives of some severe patients, (such as severely burned patients, traffic accident injured patients, patients with great operations, patients with advanced tumor and cachexia, etc.) and furthermore can be used for complementarily curing some dystrophic diseases and also can be orally taken as nutrition supplementary and auxiliary treatment. The invention can increase essential energy for body metabolism, provide biological film for body and essential 'polyunsaturated fatty acid' for biologically active substance metabolism, and prevent and correct deficiency of essential fatty acid for body. The invention has a plurality of therapeutic functions of blood sugar reduction, anti-oxidative damage, anti-anaphylaxis, anti-cell senescence, and anti-cardiovascular hardness and the like, and provides a new direct and convenient way through which edible and medical walnut effective component can enter human body.
1343154 Radioactive compositions MINNESOTA MINING & MFG CO 19 April 1971 [26 March 1970] 24717/71 Heading G6R For preparing radioactively labelled microparticles for use in medical diagnosis, a container 18 is divided into two compartments by a porous plate 22 and contains microparticles and a labelling reagent; the ends of the container are sealed by stoppers 16, 29 through which a syringe needle may be inserted for introduction of liquid or withdrawal of a suspension of the particles. The microspherical particles may consist of albumin, gelatine, hemoglobin, amylose, insulin, glycogen, colloidal sulphur, or starch, to which ferric hydroxide or silver iodide may be added. When radioteohnetium is being used, a particulate resin hydrogen ion source 24 is provided, held in place by packing 26, and a reagent tablet 20 contains sodium thiosulphate as a reducing agent together with a wetting agent to suspend the microspheres, a filler, binder, and lubricant. A solution containing radiotechnetium is introduced by means of a needle at 29 and passes through the resin 24 and filter plate 22 into compartment 21. The container is agitated, heated, cooled, and the supernatant liquid removed from the labelled microparticles, which are then suspended in saline solution and withdrawn for injection. A layer of granular alumina carrying Mo 99 in the form of ammonium molybdate may be arranged between the resin 24 and the packing 26; radiotechnetium solution is formed when saline solution is introduced through stopper 29 and passes through the alumina into the container 18.
Several substantially purified pantothenate kinase polypeptides are disclosed, as are polyclonal and monoclonal antibodies that specifically bind a pantothenate kinase. Isolated polynucleotides encoding these polypeptides are also disclosed. Vectors including these polynucleotides, and host cells transfected with these polypeptides, are also disclosed herein. Methods are also disclosed herein for treating a neurodegenerative disorder by administering a PANK polynucleotide or a PANK polypeptide to a subject. Pharmaceutical compositions are further disclosed herein that include a PANK polynucleotide or polypeptide. Methods of predicting a predisposition to, or severity of, a neurodegenerative disorder are also disclosed, as are kits useful for this detection. Also disclosed herein are methods of treating a neurodegenerative disorder in a subject.
PURPOSE: To assess the level and the determinants of compliance with outpatient retinopathy of prematurity (ROP) examination appointments at a tertiary academic center.
METHODS: The medical records of babies scheduled for outpatient ROP examination between January 1, 2022, and December 31, 2022, were reviewed retrospectively. Data collected included appointments scheduled and attended, birth weight, gestational age, ROP staging at discharge, maternal ethnicity (self-identified), household type, proximity to hospital and median family income (US Census based on home zip codes). Univariate and multivariable analyses were performed. A P value of <0.05 was considered significant.
RESULTS: The records of 66 babies were analyzed. Forty-nine babies (74%) attended all scheduled ROP examination appointments (fully compliant). The mean appointment compliance rate was 86%, with a 1.5% no-show rate. Seven children (11%) required the intervention of Child Protective Services. One baby was never seen in the clinic. In unadjusted analysis, maternal ethnicity (P = 0.028) and median family income lower than the national average (P = 0.049) were sociodemographic factors associated with lower compliance. Clinical factors associated with lower compliance were lower gestational ages (P = 0.005) and lower birth weight (P = 0.006). In multivariable logistic regression adjusting for all candidate predictors, only birth weight remained significantly associated with lower compliance (P = 0.036).
CONCLUSIONS: Clinical and sociodemographic factors may be associated with compliance with outpatient ROP examination recommendations. Extremely low-birth-weight babies were at the greatest risk for noncompliance.
A system for physiological analysis and feedback application thereof is provided. An interface receives time information recording a time slot, temperature information of a first user measured at the time slot, and a birth control setting determined by the first user. A storage device comprises a user information storage unit and a service provider information storage unit. The user information storage unit stores the time information, the temperature information, and the birth control setting, and temperature history information corresponding to the first user, wherein the temperature history information comprises a plurality of items of time information and corresponding temperature information preceding the time slot. The service provider information storage unit stores service information and service attributes corresponding to a plurality of service providers. A processor determines, according to the time information, the temperature information and the temperature history information, a ovulation status, and selects, based on the birth control setting and the ovulation status, one of the service providers having service attributes confirmed to the birth control setting and the ovulation status, and sends the service information corresponding to the selected service provider to the first user.
Overexpression of rice A20/AN1 zinc-finger protein, OsSAP10, improves water-deficit stress tolerance in Arabidopsis via interaction with multiple proteins. Stress-associated proteins (SAPs) constitute a class of A20/AN1 zinc-finger domain containing proteins and their genes are induced in response to multiple abiotic stresses. The role of certain SAP genes in conferring abiotic stress tolerance is well established, but their mechanism of action is poorly understood. To improve our understanding of SAP gene functions, OsSAP10, a stress-inducible rice gene, was chosen for the functional and molecular characterization. To elucidate its role in water-deficit stress (WDS) response, we aimed to functionally characterize its roles in transgenic Arabidopsis, overexpressing OsSAP10. OsSAP10 transgenics showed improved tolerance to water-deficit stress at seed germination, seedling and mature plant stages. At physiological and biochemical levels, OsSAP10 transgenics exhibited a higher survival rate, increased relative water content, high osmolyte accumulation (proline and soluble sugar), reduced water loss, low ROS production, low MDA content and protected yield loss under WDS relative to wild type (WT). Moreover, transgenics were hypersensitive to ABA treatment with enhanced ABA signaling and stress-responsive genes expression. The protein-protein interaction studies revealed that OsSAP10 interacts with proteins involved in proteasomal pathway, such as OsRAD23, polyubiquitin and with negative and positive regulators of stress signaling, i.e., OsMBP1.2, OsDRIP2, OsSCP and OsAMTR1. The A20 domain was found to be crucial for most interactions but insufficient for all interactions tested. Overall, our investigations suggest that OsSAP10 is an important candidate for improving water-deficit stress tolerance in plants, and positively regulates ABA and WDS signaling via protein-protein interactions and modulation of endogenous genes expression in ABA-dependent manner.
Presence of a SIRD phenotype will be examined according to the parameters de-scribed Ahlqvist et al (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).
PROBLEM TO BE SOLVED: To obtain the vaccine based on a recombined vector obtained by inserting an avian immune source into an avian helpes virus, also effective for Bumboro disease having been difficult in prevention and capable of protecting fowls from death and fabricius infectious bursal diseases. SOLUTION: This live recombinant avian vaccine comprises, as a vector, an avian herpes virus comprising at least one nucleotide sequence coding for and expressing an antigenic polypeptide of an avian pathogenic agent, and inserted into the region lying between the ATG of ORF-UL55 and the junction of UL with the adjacent repeat region, under the control of the CMV immediate early promoter. The vector is preferably Marek's disease virus, especially herpes virus of ducks, and the insertion region is preferably one of the intergenetic regions 1, 2 and 3, or ORF UL55 of the BamHI fragment I. The CMV-immediate early promoter is e.g. the human promoter MCMV-IE. The nucleotide sequence is preferably a nucleotide sequence coding for the polypeptide VP2 of the Gumboro disease.
Fatigue, sleep disturbance, and depression commonly co-occur in breast cancer (BC) survivors, forming a significant cluster known as the fatigue-sleep disturbance-depression symptom cluster (FSDSC). The FSDSC correlates notably with decreased everyday functioning and quality of life (QoL). Currently, there are no targeted pharmacological interventions available for alleviating the FSDSC in BC survivors. Additionally, concerns arise regarding the risks of drug-related adverse events and potential interactions with ongoing antineoplastic regimens when relying solely on pharmacological treatments. Consequently, nonpharmacological adjunct interventions have emerged as an alternative method. Somatic acupressure (SA) presents a promising nonpharmacological intervention for managing the FSDSC due to its advantages, including self-administration with minimal effort and time, lower cost, good tolerability, and minimal instruction required from clinical staff. However, the effectiveness of SA in improving the FSDSC in BC survivors remains uncertain. The proposed study follows the Medical Research Council (MRC) Framework for Developing and Evaluating Complex Intervention (the MRC Framework) to develop an evidence-based SA protocol to help with the better management of the FSDSC in BC survivors. The first phase identified and validated the most effective acupoint formula with the optimal SA duration and frequency based on multiple evidence bases. Subsequently, a well-designed phase II randomized controlled trial (RCT) was conducted. It demonstrated the feasibility of an evidence-based SA intervention protocol and its potentially positive effects on the FSDSC in BC survivors. The encouraging results, therefore, warrant further investigation through a large-scale RCT to ascertain the effects of SA on the FSDSC among BC survivors. The whole program is designed following the MRC Framework. Hence, the current study aims to evaluate the effects, safety, and cost-effectiveness of the SA protocol for managing the FSDSC in BC survivors through a phase III RCT.